NASDAQ$NTRA
Natera Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported strong volume growth, consistent average selling price expansion, and reduced cost of goods sold per unit in its reproductive health business.
Natera reported a 24% increase in total revenues for Q4 2019, driven by sales of Panorama and Horizon tests. The company processed 209,400 tests, with 198,300 accessioned in its laboratory, and recognized revenue on 200,800 tests reported, including 189,700 tests accessioned in its laboratory.
- Total revenues increased by 24% compared to Q4 2018.
- Processed 209,400 tests in Q4 2019, a 20% increase year-over-year.
- Gross profit for Q4 2019 was $38.8 million, representing a 47% gross margin.
- Net loss for Q4 2019 was $35.2 million, or ($0.46) per diluted share.
Headline financials
Revenue & EPS history
Natera · Revenue · Quarterly
$83.2M
Revenue by segment
Natera · $33.9M total across 1 segment · Q1 2021
- Licensing and other revenues$33.9M—100.0%
Forward guidance
Natera anticipates 2020 total revenue of $335 million to $350 million; 2020 cost of revenues to be approximately 51% to 57% of revenues; selling, general and administrative costs to be approximately $240 million to $260 million; research and development costs to be $80 million to $90 million, and net cash burn to be $125 million to $150 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+4.4%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+6.0%
Avg return
30 days after
69%
31 / 45 earnings
Positive
+29.1%
Q2 2017
Best reaction
-21.2%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.0% | -5.2% | +0.0% | |
| Q4 2025 | -3.8% | -6.0% | -15.5% | |
| Q3 2025 | +0.7% | +5.6% | +23.2% | |
| Q1 2025 | -6.9% | -6.9% | +0.7% | |
| Q4 2024 | -0.7% | -5.5% | -8.1% | |
| Q3 2024 | +20.2% | +9.0% | +24.2% | |
| Q2 2024 | +14.2% | +18.6% | +12.5% | |
| Q1 2024 | +10.1% | +10.3% | +16.2% | |
| Q4 2023 | +13.6% | +18.4% | +20.1% | |
| Q3 2023 | +4.0% | +11.2% | +33.2% | |
| Q2 2023 | +16.1% | +20.0% | +42.3% | |
| Q1 2023 | -3.6% | -3.8% | -8.1% | |
| Q4 2022 | +14.1% | +22.2% | +14.1% | |
| Q3 2022 | -13.2% | -5.3% | -9.2% | |
| Q2 2022 | +5.1% | +3.7% | -2.7% | |
| Q1 2022 | -2.0% | -18.5% | +0.5% | |
| Q4 2021 | +10.2% | +5.9% | -34.7% | |
| Q3 2021 | +3.6% | +1.2% | -22.7% | |
| Q2 2021 | +2.4% | -7.7% | +8.1% | |
| Q1 2021 | -2.9% | -14.0% | -7.1% | |
| Q4 2020 | +2.9% | +4.6% | -17.0% | |
| Q3 2020 | +9.3% | +2.3% | +16.5% | |
| Q2 2020 | +11.8% | +4.0% | +31.2% | |
| Q1 2020 | +19.8% | +28.3% | +11.6% | |
| Q4 2019 | +6.4% | +5.6% | -27.3% | |
| Q3 2019 | -3.7% | +0.3% | -1.3% | |
| Q2 2019 | +19.3% | +9.6% | +19.8% | |
| Q1 2019 | +19.8% | +26.8% | +34.3% | |
| Q4 2018 | +19.6% | +16.9% | +22.9% | |
| Q3 2018 | -21.2% | -25.2% | -20.4% | |
| Q2 2018 | +0.2% | +5.2% | +8.4% | |
| Q1 2018 | +1.4% | -0.9% | +3.6% | |
| Q4 2017 | +0.3% | +17.3% | +10.1% | |
| Q3 2017 | -12.8% | -13.4% | -11.9% | |
| Q2 2017 | +29.1% | +32.4% | +64.0% | |
| Q1 2017 | +13.8% | +11.5% | +7.1% | |
| Q4 2016 | -14.8% | -15.9% | -10.8% | |
| Q3 2016 | +12.0% | +25.5% | +26.8% | |
| Q2 2016 | -5.8% | -17.2% | -21.3% | |
| Q1 2016 | +15.4% | — | — | |
| Q1 2014 | +0.1% | — | — | |
| Q4 2015 | -13.8% | — | — | |
| Q3 2014 | +2.7% | — | — | |
| Q3 2015 | +7.0% | — | — | |
| Q2 2014 | -3.6% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro